OM1 Expands Neurology Network to Over 3 Million Patients, Bolstering Real-World Evidence and Advancing Innovation in Neurological Care

OM1, a leader in real-world evidence (RWE) generation and AI-driven insights for healthcare and life sciences, has announced the expansion of its Neurology Specialty Network with the addition of 500,000 patients. The network now encompasses over 3 million individuals, drawing from electronic health records and clinical notes by neurology specialists, making it one of the most comprehensive and clinically detailed sources of real-world data in neurology. This expansion significantly strengthens OM1’s PremiOM™ datasets for key neurological conditions, including Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease, with notable growth in data for migraine headaches and amyotrophic lateral sclerosis (ALS). The resulting research-ready datasets combine structured and unstructured clinical data, medical and pharmacy claims, and curated outcomes, all enhanced by advanced AI models. This integration enables faster, more accurate, and deeper real-world evidence generation across the full neurology care continuum. “Expanding our neurology network to more than 3 million patients marks a pivotal milestone in advancing care for patients with complex neurological conditions,” said Dr. Carl Marci, Chief Clinical Officer and Managing Director of Mental Health and Neuroscience at OM1. “By combining rich clinical data with cutting-edge AI, we’re empowering researchers and healthcare providers with tools to uncover critical insights into disease progression, treatment effectiveness, and the potential for more personalized, precision-based care.” The enhanced neurology network is also integrated with OM1’s other specialty networks, including Primary Care—serving over 22 million patients—and Mental Health, with more than 6 million patients. This interconnected data ecosystem provides a holistic view of the patient journey, from initial symptoms and diagnosis through long-term treatment and outcomes. This comprehensive perspective allows stakeholders to conduct more robust, real-world studies that reflect the complexities of actual clinical practice. Neurological disorders are a global health priority, ranking as the leading cause of disability and the second leading cause of death worldwide, according to the World Health Organization. The need for high-quality, real-world data to inform treatment development, policy, and clinical decision-making has never been greater. With its expanded data assets and AI-powered analytics, OM1 is well-positioned to accelerate innovation in neurology research, support the development of new therapies, and advance personalized medicine. The company continues to leverage its deep expertise in real-world evidence, longitudinal data, and AI to drive transformative insights for life sciences organizations, healthcare providers, and patients alike. OM1 is at the forefront of healthcare innovation, combining a multidisciplinary team of scientists, engineers, researchers, and clinicians with over 30 years of experience in real-world evidence. The company’s mission is to unlock the full potential of data to improve health outcomes through intelligent, evidence-based solutions.